Literatur
- 1
Albers J J, Taggart H M, Applebaum-Bowden D, Haffner S, Chesnut CH 3 d, Hazzard W R.
Reduction
of lecithin-cholesterol acyltransferase, apolipoprotein D and Lp(a)
with the anabolic steroid stanazolol.
Biochem Biophys Acta.
1984;
795
293-296
- 2
Almendingen K, Jordal O, Kierulf P, Sandstad B, Pederson J I.
Effects of
partially hydrogenated fish oil, partially hydrogenated soybean oil,
and butter on serum lipoproteins and Lp(a) in men.
J Lipid
Res.
1995;
36
1370-1384
- 3
Bausserman L L, Saritelli A L, Herbert P N.
Effects
of shot-term stanazolol administration on serum lipoproteins in
hepatic lipase deficiency.
Metabolism.
1997;
46
992-996
- 4
Berg K, Dahlen G, Frick M H.
Lp(a) lipoprotein
and pre-beta1 lipoprotein in patients with coronary heart disease.
Clin
Genet.
1975;
6
330-335
- 5
Berglund L, Carlström K, Stege R, Gottlieb C, Eriksson M, Angelin B, Henriksson P.
Hormonal
Regulation of serum lipoprotein(a) levels: Effects of parenteral
administration of estrogen or testosterone in males.
J
Clin Endocrinol Metabol.
1996;
81
2633-2637
- 6
Berglund L.
Diet
and drug therapy for lipoprotein(a).
Curr Opin Lipidol.
1995;
6
48-56
- 7
Bostom A G, Cupples L A, Jenner J L, Ordovas J M, Seman L J, Wilson P W, Schaefer E J,
Castelli W P.
Elevated
plasma lipoprotein(a) and coronary heart disease in men aged 55
years and younger. A prospective study.
JAMA.
1996;
276
544-548
- 8
Cantin B, Gagnon F, Moorjani S, Després J P, Lamarche B, Lupien P J, Dagenais G R.
Is lipoprotein(a)
an independent risk factor for ischemic heart disease in men? The
Quebec cardiovascular study.
JACC.
1998;
31
519-525
- 9
Carlson L A, Hamsten A, Asplund A.
Pronounced
lowering of serum lipoprotein Lp(a) in hyperlipemic subjects treated
with nicotinic acid.
J Intern Med.
1989;
226
271
- 10
Corsetti J P, Sterry J A, Sparks J D, Sparks C E, Weintraub M.
Effect
of weight loss on serum lipoprotein(a) concentrations in an obese population.
Clin
Chem.
1991;
37
1191-1195
- 11
Cremer P, Nagel D, Labrot B, Mann H, Müller-Berninger R, Elster H, Seidel D.
Ten-year follow-up results
from the Goettingen risk, incidence and prevalence study (GRIPS).
I. Risk factors for myocardial infarction in a cohort of 5790 men.
Atherosclerosis.
1997;
129
221-230
- 12
Daida H, Lee Y J, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H,
Kutsumi Y, Yamada N, Noma A, Yamaguchi H. and the low-density
lipoprotein apheresis angioplasty restenosis trial (L-Art) group .
Prevention of restenosis after percutaneous transluminal coronary
angioplasty by reducing lipoprotein (a) levels with low-density
lipoprotein apheresis.
Am J Cardiol.
1994;
73
1037-1040
- 13
Davoren P M, Kelly W, Gries F A, Hubinger A, Whately-Smith C, Alberti K G.
Long-term
effects of a sustained-release preparation of acipimox on dyslipidemia
and glucose metabolism in non-insulin-dependent diabetes mellitus.
Metabolism.
1998;
47
250-256
- 14
Desmarais R L, Sarembock I J, Ayers C R, Vernon S M, Powers E R, Gimple L W.
Elevated serum
lipoprotein(a) is a risk factor for clinical recurrence after coronary
balloon angioplasty.
Circulation.
1995;
91
1403-1409
- 15
Dieplinger H, Kronenberg F.
Genetics and metabolism
of lipoprotein(a) and their clinical implications (Part 1).
Wien
Klin Wochenschr.
1999;
111
5-20
- 16
Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M.
Serum Lp(a) lipoprotein
levels in patients with coronary artery disease and the influence
of long-term n-3 fatty acid supplementation.
Scand J Clin lab
Invest.
1995;
55
295-300
- 17
Espeland M A, Marcovina S M, Miller V, Wood P D, Wasilauskas C, Sherwin R, Schrott H,
Bush T L.
Effect of postmenopausal
hormone therapy on lipoprotein(a) concentration. PEPI investigators.
Postmenopausal estrogen/progestin interventions.
Circulation.
1998;
97
979-986
- 18
Garry P, Collins P, Devlin J G.
An open 36
month study of lipid changes with growth hormone in adults: lipid
changes following replacement of growth hormone in adult acquired
growth hormone deficiency.
Eur J Endocrinol.
1996;
134
61-66
- 19
Georgala S, Schulpis K H, Potouridou I, Papadogeorgaki H.
Effects of isotretionin
therapy on lipoprotein(a) serum levels.
Int J Dermatol.
1997;
36
863-864
- 20
Ginsberg H N, Kris-Etherton P, Dennis B, Elmer P J, Ershow A, Lefevre M, Pearson T,
Roheim P, Ramakrishnan R, Reed R, Srewart K, Stewart P, Phillips K, Anderson N.
Effects
of reducing dietary saturated fatty acids on plasma lipids and lipoproteins
in healthy subjects: the DELTA-Study, protocol 1.
Arterioscler
Thromb Vasc Biol.
1998;
18
441-449
- 21
Giri S, Thompson P D, Taxel P, Contois J H, Otvos J, Allen R, Ens G, WU A h, Waters D D.
Oral
estrogen improves serum lipids, homocysteine and fibrinolysis in
elderly men.
Atherosclerosis.
1998;
137
359-366
- 22
Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E.
Effect of
oral estradiol of Lp(a) and other lipoproteins in postmenopausal women.
Arch
Intern Med.
1996;
156
866-872
- 23
Haskell W L, Camargo C Jr, Williams P T, Vranizan K M, Krauss R M, Lindgren F T,
Wood P D.
The
effect of cessation and resumption of moderate alcohol intake on
serum high-density-lipoprotein subfractions.
N Engl J Med.
1984;
310
805-810
- 24
Herrmann W, Biermann J, Kostner G M.
Comparison
on effects of n-3 to n-6 fatty acids on serum level of lipoprotein(a)
in patients with coronary artery disease.
Am J Cardiol.
1995;
76
459-462
- 25
Holme I, Urdal P, Anderssen S, Hjermann I.
Exercise-induced
increase in lipoprotein(a).
Atherosclerosis.
1996;
122
97-104
- 26
Jones P H, Pownell H J, Patsch W, Herd J A, Farmer J A, Payton-Ross C, Kimball K T,
Gotto A M, Morrisett J D.
Effect
of gemfibrozil on levels of lipoprotein(a) in type II hyperlipoproteinemic
subjects.
J Lipid Res.
1996;
37
1298-1308
- 27 Kostner G M, Klein G, Krempler F. Can
serum Lp(a) concentrations be lowered by drugs and/or by
diet?. In: Carlsson/Olsson (Hrsg.). Treatment
of hyperlipoproteinemia Raven, New-York 1994: 151-156
- 28
Kronenberg F, Kronenberg M, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G,
Utermann G, Willeit J.
Role
of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis.
Results from the Bruneck study.
Circulation.
1999;
100
1154-1160
- 29
Kronenberg F, Neyer U, Lhotta K, Trenwalder E, Auinger M, Pribasnig A, Meisl T, König P,
Diepliger H.
Low molecular weight
apo(a) phenotyp is an independent predictor for coronary artery
disease in hemodialysis patients. A prospective follow up.
J
Am Soc Nephrol.
1999;
10
1027-1036
- 30
Kronenberg F, Utermann G, Dieplinger H.
Lipoprotein(a)
in renal disease.
Am J Kidn Dis.
1996;
27
1-25
- 31
Laron Z, Wang X L, Klinger B, Silbergeld A, Wilcken D E.
Growth hormone
increases and insulin-like growth factor decreases circulating lipoprotein(a).
Eur
J Endocrinol.
1997;
136
377-381
- 32
Mackinnon L T, Hubinger L, Lepre F.
Effects
of physical activity and diet on lipoprotein(a).
Med Sci
Sports Exerc.
1997;
29
1429-1436
- 33
Malarkey W B, Strauss R H, Leizman M, Liggett M, Demers L M.
Endocrine
effects in female weight lifters who selfadminister testosterone
and anabolic steroids.
Am J Obstet Gynecol.
1991;
165
1385-1390
- 34
Olivecrona H, Ericsson S, Berglund L, Angelin B.
Increased concentrations
of serum lipoprotein(a) in response to growth hormone treatment.
BMJ.
1993;
306
1726-1727
- 35
Oscarsson J, Lundstam U K, Gustaffson B, Wilton P, Edén S, Wiklund O.
Recombinant human insulin-like
growth factor-1 decreases serum lipoprotein(a) concentrations in
normal adult men.
Clin Endocrinol.
1995;
42
673-676
- 36
Oscarsson J, Ottoson M, Wiklund O, Marin P, Vikman-Adolfsson K, Bjorntorp P, Edén S.
Low-dose
continously infused growth hormone results in increased lipoprotein(a)
and decreased low density lipoprotein cholesterol concentrations
in middle-aged men.
Clin Endocrinol.
1994;
41
109-116
- 37
Paassilta M, Kervinen K, Rantala A O, Savolainen M J, Lilja M, Reunanen A, Kesaniemi Y A.
Social
alcohol consumption and low Lp(a) lipoprotein concentrations in
middle aged Finnish men: population based study.
BMJ.
1998;
316
594-595
- 38
Ramharack R, Spahr M A, Sekerke C S, Stanfield R L, Bousley R F, Lee H T, Krause B K.
CI-1011
lowers lipoprotein(a) and plasma cholesterol in chow-fed cynomolgus
monkeys.
Atherosclerosis.
1998;
136
79-87
- 39
Rimm E B, Giovannucci E L, Willet W C, Colditz G A, Ascherio A, Rosner B, Stampfer M J.
Prospective
study on alcohol consumption and risk of coronary disease in men.
Lancet.
1991;
338
464-468
- 40
Rosén T, Bengtsson B Å.
Premature
mortality due to cardiovascular disease in hypopituitarism.
Lancet.
1990;
336
285-288
- 41
Sacks F M, Walsh B W.
Sex hormones
and lipoprotein metabolism.
Curr Opin Lipidol.
1994;
5
236-240
- 42
Seed M, O"Connor B, Perombelon N, O"Donnell M, Reaveley D, Knight B L.
The
effect of nicotinic acid and acipimox on lipoprotein(a) concentration
and turnover.
Atherosclerosis.
1993;
101
61-68
- 43
Shinozaki K, Kambajyshi J, Kawasaki T, Uemura Y, Sakon M, Shiba E, Shibuya T, Nakamura T,
Mori T.
The long-term effect of
eicosapentaenoic acid on serum levels of lipoprotein(a) and lipids
in patients with vascular disease.
J Atheroscler Thromb.
1996;
2
107-109
- 44
Sonnichsen A C, Richter W O, Schwandt P.
Reduction
of lipoprotein(a) by weight loss.
Int J Obes.
1990;
14
487-494
- 45
Tanaka K, Hayashi K, Shingu T, Kuga Y, Okura Y, Yasunobu Y, Ohtani H, Momura S, Kurushima H,
Saeki M, Kambe M, Kajiyama G.
Pentaerythritol
tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
Metabolism.
1997;
46
355-358
- 46
Thiery J, Armstrong V W, Schleef J, Creutzfeld C, Creutzfeld W, Seidel D.
Serum lipoprotein(a)
concentrations are not influenced by an HMG CoA reductase inhibitor.
Klin
Wochenschr.
1988;
66
462-463
- 47
Thiery J, Ivandic B, Bahlmann G, Walli A K, Seidel D.
Hyperlipoprotein(a)emia
in nephrotic syndrome.
Eur J Clin Invest.
1996;
26
316-321
- 48
Thiery J, Seidel D.
Safety and effectiveness
of long-term LDL-apheresis in patients at high risk.
Curr
Opin Lipidol.
1998;
9
521-526
- 49
Tholstrup T, Marckmann P, Vessby B, Sandström B.
Effects of
fat high individuell satuarated fatty acids on plasma lipoprotein(a)
in young healthy men.
J Lipid Res.
1995;
36
1447-1452
- 50
Tuck C H, Holleran S, Berglund L.
Hormonal
regulation of lipoprotein(a) levels: effects of estrogen replacement
therapy on lipoprotein(a) and acute phase reactants in postmenopausal
women.
Arterioscler Thromb Vasc Biol.
1997;
17
1822-1829
- 51
Ullrich H, Lackner K, Schmitz G.
Lipoprotein
(a)- apheresis in the secondary prevention of coronary heart disease.
Transfus
Sci..
1997;
17
511-517
- 52
Velazquez E M, Mendoza S G, Wang P, Glueck C J.
Metformin therapy
is associated with a decrease in plasma plasminogen activator inhibitor-1,
lipoprotein(a), and immunoreactive insulin levels in patients with
the polycystic ovary syndrome.
Metabolism.
1997;
46
454-457
- 53
Vessby B, Kostner G, Lithell H, Thomis J.
Diverging effects of
cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose
response study of the effects of cholestyramine in hypercholesterolaemia.
Atherosclerosis.
1982;
44
61-71
- 54
White A L, Lanford R E.
Biosynthesis
and metabolism of lipoprotein(a).
Curr Opin Lipidol.
1995;
6
136-145
- 55
Straube R, Kingreen H.
Lipoprotein (a) immunapheresis
in the treatment of familial lipoprotein(a) hyperlipoproteinemia
in a patient with coronary heart disease.
Ther Apher.
1998;
2(3)
243-245
Korrespondenz
Hans-Peter Thomas
Lipidambulanz/LDL-Apherese
Medizinische
Poliklinik Charité Campus Virchow-Klinikum
Mittelallee 11
13353 Berlin
Telefon: 030-450 53340
Fax: 030-450 53905
eMail: hans-peter.thomas@charite.de
